Evaluation of Vildagliptin (Galvus®) as add-on to Insulin in New-onset Type 1 Diabetes Mellitus
Status:
Unknown status
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the action of DPP-IV inhibitors in the
prevention of progressive beta cell dysfunction in patients with type 1 diabetes mellitus
newly diagnosis ( less than 6 months).
The secondary objectives are:
1. To define the immune and inflammatory profile
2. To define the secretion of glucagon and GLP-1
3. To assess the glycemic variability
Phase:
Phase 3
Details
Lead Sponsor:
Federal University of São Paulo
Collaborator:
Novartis
Treatments:
Dipeptidyl-Peptidase IV Inhibitors Insulin Insulin, Globin Zinc Vildagliptin